Antiva Biosciences Closes $31 Million Series D Equity Financing

/PRNewswire/ -- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by...

Related Keywords

World Health Organization ,Al Qahirah ,Egypt ,Japan ,Alexandria ,Al Iskandariyah ,Clifford Samuel ,Gail Maderis ,Tim Brons ,Jenny Yip ,Prnewswire Antiva Biosciences ,Antiva Biosciences ,Karl Hostetler ,University Of California San Diego ,Global Patient Solutions At Gilead ,Antiva Biosciences Inc ,Osage University Partners ,Adjuvant Capital ,Healthcare Investments ,Avestria Ventures ,Mana Ventures ,Canaan Partners ,Sofinnova Ventures ,Lumira Ventures ,Pharma Capital ,Sirona Capital ,Alexandria Venture ,Managing Partner ,Senior Vice President ,Global Patient Solutions ,Related Diseases ,Papilloma Virus ,South San Francisco ,California San ,Strategic Partners ,Nc ,